RK, this is pretty simple. Orders of magnitude more simple than your posts. I have long understood that neoantigens are natural targets for killer T-Cells. The subgroups have nothing to do with that. This is true for all cancers.
The issue is that Prins said in the Q/A after his recent lecture that the next area of focus is reducing the disadvantage that results from going after all the lysate antigens, rather than just the neoantigens. he didn't say that the reason it was an issue was due to DC migration pathway crowding, but since Pyrrhonian recently brought up that issue regarding some recent findings, and the two issues would be consistent, I am wondering if that is the mechanism that creates the disadvantage that Prins spoke about.
Prins does not say this is a huge issue, he just says it is the area next needed improving.
Maybe the reason that DCVax-L DC's taking up tons of useless self-antigen in addition to valuable neoantigen is less than optimum has nothing to do with DC migration pathway crowding... but it would make sense if that turned out to be the reason.
At any rate, focusing on isolation of neoantigens is what Prins says they are working on.
The fact that the T-Cells respond only to neoantigens does not help the DC's in DCVax-L getting overwhelmed by having to pick-up so many self antigens, which is apparently somewhat the case according to Prins. The T-Cells are step B. We are talking about Step A. Step B makes this issue in Step A a non-issue, on paper, sort of, but apparently, in the end, it is not a non-issue, according to Prins.
News 
Market Data 
Discover 
AI
